Fenoldopam description

Revision as of 03:44, 27 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Fenoldopam}} {{CMG}}; {{AE}} {{SS}} ==Description== Corlopam (Fenoldopam Mesylate Injection, USP) is a dopamine D1-like receptor agonist. The product is formulat...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Fenoldopam
CORLOPAM® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fenoldopam
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Description

Corlopam (Fenoldopam Mesylate Injection, USP) is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-7,8-diol methanesulfonate with the following structure:



fenoldopam mesylate

Fenoldopam mesylate is a white to off-white powder with a molecular weight of 401.87 and a molecular formula of C16H16ClNO3•CH3SO3H. It is sparingly soluble in water, ethanol and methanol, and is soluble in propylene glycol.

Ampules: Each 1 mL contains, in sterile aqueous solution, citric acid 3.44 mg; fenoldopam mesylate equivalent to fenoldopam 10 mg; propylene glycol 518 mg; sodium citrate dihydrate 0.61 mg; sodium metabisulfite 1 mg.

[1]


References

  1. "CORLOPAM (FENOLDOPAM MESYLATE) INJECTION, SOLUTION [HOSPIRA, INC.]". Retrieved 26 February 2014.

Template:Sympatholytic antihypertensives